Amphastar Pharmaceuticals (NASDAQ:AMPH)‘s stock had its “market perform” rating restated by equities research analysts at BMO Capital Markets in a report released on Tuesday. They currently have a $19.00 price target on the stock, up from their previous price target of $17.00. BMO Capital Markets’ price target points to a potential downside of 5.00% from the stock’s previous close.
Several other equities research analysts have also recently issued reports on AMPH. BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. Needham & Company LLC boosted their price target on Amphastar Pharmaceuticals from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday. Piper Jaffray Companies reiterated a “buy” rating and issued a $26.00 price target on shares of Amphastar Pharmaceuticals in a research note on Tuesday, January 30th. Finally, Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $21.33.
Shares of Amphastar Pharmaceuticals (AMPH) traded down $0.35 during trading hours on Tuesday, hitting $20.00. The stock had a trading volume of 47,962 shares, compared to its average volume of 195,051. Amphastar Pharmaceuticals has a 12 month low of $12.10 and a 12 month high of $20.45. The company has a market capitalization of $900.21, a PE ratio of 226.11, a PEG ratio of 1.16 and a beta of 1.46. The company has a current ratio of 3.08, a quick ratio of 1.86 and a debt-to-equity ratio of 0.13.
In other news, General Counsel Jason B. Shandell sold 8,661 shares of the company’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $19.26, for a total transaction of $166,810.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen B. Shohet sold 7,866 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $18.87, for a total transaction of $148,431.42. Following the transaction, the director now owns 31,982 shares of the company’s stock, valued at $603,500.34. The disclosure for this sale can be found here. Insiders have sold 35,677 shares of company stock valued at $687,167 over the last 90 days. Corporate insiders own 11.10% of the company’s stock.
Large investors have recently made changes to their positions in the company. Paloma Partners Management Co acquired a new position in shares of Amphastar Pharmaceuticals during the fourth quarter worth $197,000. Stone Ridge Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the fourth quarter worth $214,000. Renaissance Technologies LLC acquired a new position in shares of Amphastar Pharmaceuticals during the fourth quarter worth $227,000. Driehaus Capital Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the fourth quarter worth $229,000. Finally, Municipal Employees Retirement System of Michigan increased its holdings in shares of Amphastar Pharmaceuticals by 58.8% during the third quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock worth $239,000 after buying an additional 4,960 shares in the last quarter. Institutional investors own 44.82% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “BMO Capital Markets Reiterates “Market Perform” Rating for Amphastar Pharmaceuticals (AMPH)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/13/amphastar-pharmaceuticals-amph-pt-raised-to-19-00-at-bmo-capital-markets.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.